Genmab — Januar 2019
-
at der så er nogen herinde, der opfatter det som om jeg ikke ser værdi i aktien, er temmelig meget ud over min forstand
-
...hvad pipelinen indeholder er en helt anden diskussion - jeg påpeger blot, at dara-værdien ikke bliver afspejlet i kursen - og at pipelinen (I min optik) bliver handlet til negativ værdi
-
1030
-
lige nu venter jeg bare på at grippen kommer - GEN lader til at være uinteresseret i investorerne
-
Portugal har godkendt dara ? https://translate.google.com/translate?sl=pt&tl=da&u=http%3A
%2F%2Fviglya.com%2Finfarmed-novo-medicamento-para-tratamento-em-doentes-oncologicos-darzalex-daratumumab-avaliacao-previa-hospitalar-concluida%2F -
"
Scope: Submission of study report of study SMM2001: a randomised phase 2 trial to evaluate 3 daratumumab dose schedules in smouldering multiple myeloma. As a consequence, the RMP is updated (version 4.1) in order to remove QTc prolongation as an important potential risk"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind